U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
GHENT, Belgium, 4 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday 8 January 2018 at 09:30 a.m. Pacific Standard Time (06:30 p.m. Central European Time).
The presentation will be hosted by Dr Edwin Moses, CEO of Ablynx, and will be followed by a Q&A break-out session. The presentation will provide an overview of the major achievements in 2017 as well as an update on the Company's proprietary key clinical assets, its partnered programmes and the outlook for 2018. During this conference, Ablynx will also hold one-on-one meetings with institutional investors.
The presentation will be webcast live and can be accessed on the day via this link. The presentation will be available on the Company's website, under the News & Events section for 90 days following the event.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: [email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/ee194110-ba51-4e4a-a5f3-8ced0aa1ec1f
